問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiation Therapy

Division of Radiation Therapy

Division of Radiation Therapy

更新時間：2023-09-19

黃炳勝
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃炳勝

List

5Cases

2017-01-20 - 2025-08-15

Phase III

Completed
A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)

  • Condition/Disease

    Head and Neck Neoplasms

  • Test Drug

    Keytruda

Participate Sites
7Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

楊慕華
Taipei Veterans General Hospital

Division of Radiation Therapy

2025-03-01 - 2026-12-31

Others

Active
A prospective study using gallium-68-Dorec gallium dynamic positron emission tomography to assess residual liver function in liver cancer patients before and after proton therapy.

  • Condition/Disease

    Diagnostic drugs for liver function

  • Test Drug

    Nuclear research on Dorex gallium liver function contrast agent

Participate Sites
1Sites

Recruiting1Sites

2023-08-01 - 2024-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2010-12-01 - 2020-12-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated6Sites

Suspended3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB